TipRanks
Advertisement
Advertisement
Ram Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential
PremiumRatingsRam Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential
1M ago
Axsome Therapeutics price target raised to $316 from $306 at Mizuho
Premium
The Fly
Axsome Therapeutics price target raised to $316 from $306 at Mizuho
2M ago
Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital
Premium
The Fly
Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital
2M ago
Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating
PremiumRatingsAuvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating
2M ago
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
Premium
Ratings
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
2M ago
Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure
Premium
Ratings
Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―